SCHEMBL16620945

SCHEMBL16620945

CC=CC=CC=C(C#N)C#N

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
APP P05067 4/20 0.43
ALDH1A1 P00352 1/20 0.33
SNCA P37840 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16620943 1.00 APP (0.43) APPALDH1A1SNCA
SCHEMBL16335431 0.89
SCHEMBL14330126 0.89
SCHEMBL13893498 0.77 ALDH1A1 (0.32) ALDH1A1
SCHEMBL9244034 0.75 APP (0.30) APP
SCHEMBL20647129 0.73 APP (0.40) APPSNCA
SCHEMBL8411026 0.70 APP (0.36) APP
SCHEMBL24595282 0.70 TSHR (0.30)
SCHEMBL9361086 0.70 KDM4E (0.35) APPALDH1A1
SCHEMBL9361093 0.70 KDM4E (0.35) APPALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190070320-A1 ORGANOMEDICINALS FOR IMAGING AND TREATMENT OF NEURODEGENERATIVE DISORDERS WASHINGTON UNIVERSITY 2019-03-07 US claimed
US-20160213792-A1 HETEROCYCLIC MOLECULES FOR BIOMEDICAL IMAGING AND THERAPEUTIC APPLICATIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-07-28 US claimed
US-10335504-B2 Heterocyclic molecules for biomedical imaging and therapeutic applications WASHINGTON UNIVERSITY (US) 2019-07-02 US disclosed
US-20190070320-A1 ORGANOMEDICINALS FOR IMAGING AND TREATMENT OF NEURODEGENERATIVE DISORDERS WASHINGTON UNIVERSITY 2019-03-07 US disclosed
US-20160213792-A1 HETEROCYCLIC MOLECULES FOR BIOMEDICAL IMAGING AND THERAPEUTIC APPLICATIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-07-28 US disclosed
WO-2015051188-A1 HETEROCYCLIC MOLECULES FOR BIOMEDICAL IMAGING AND THERAPEUTIC APPLICATIONS WASHINGTON UNIVERSITY (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10335504-B2 Heterocyclic molecules for biomedical imaging and therapeutic applications APP, PSEN1, BACE1 APP 1/4885ALDH1A1 2007/4885SNCA 124/4885
US-20190070320-A1 ORGANOMEDICINALS FOR IMAGING AND TREATMENT OF NEURODEGENERATIVE DISORDERS TARDBP, GRN, FUS APP 101/4885ALDH1A1 4277/4885SNCA 17/4885
US-20160213792-A1 HETEROCYCLIC MOLECULES FOR BIOMEDICAL IMAGING AND THERAPEUTIC APPLICATIONS APP, PSEN1, BACE1 APP 1/4885ALDH1A1 2007/4885SNCA 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.